{"id":1006631,"date":"2026-09-29T10:55:09","date_gmt":"2026-09-29T14:55:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\/"},"modified":"2026-09-29T10:55:09","modified_gmt":"2026-09-29T14:55:09","slug":"20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\/","title":{"rendered":"20\/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest\u2122 Franchise Model"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>President and CEO Jonathan Cohen to Discuss Implications for Multi-Cancer Early Detection, Preliminary Interest from Laboratories Across the United States, and New State Funding for Firefighter Cancer Screening<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Webinar to Be Held Wednesday, October 7, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open<\/p>\n<p><\/em>\n      <\/p>\n<p align=\"justify\">GAITHERSBURG, Md., Sept.  29, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dRBC9yQYBvo0upgtOWKcBeTleRFW0vcKwwG0pJ8r0Pa1Mew1d1OX7ErTxQT-jx7g3VAJM_3vS4Xlh-FHB2EwqbwhEPY3GA5dUZ36PEfd6WU=\" rel=\"nofollow\" target=\"_blank\"><u>20\/20 BioLabs, Inc.<\/u><\/a> (Nasdaq: AIDX) (\u201c20\/20 BioLabs\u201d or the \u201cCompany\u201d), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it will host an investor webinar on Wednesday, October 7, 2026, at 12:00 p.m. Eastern time.<\/p>\n<p align=\"justify\">Jonathan Cohen, President and Chief Executive Officer of 20\/20 BioLabs, will discuss the September 23, 2026 meeting of the U.S. Food and Drug Administration\u2019s Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee and what management believes the panel\u2019s deliberations may indicate for the broader multi-cancer early detection (\u201cMCED\u201d) category. Mr. Cohen will also discuss the Company\u2019s newly introduced OneTest\u2122 franchise model, preliminary interest from laboratories across the United States, and new state funding initiatives for firefighter cancer screening.<\/p>\n<p align=\"justify\">To access the webinar, please use the following information:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td>\n            <strong>Date:<\/strong>\n          <\/td>\n<td>Wednesday, October 7, 2026<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Time:<\/strong>\n          <\/td>\n<td>12:00 p.m. Eastern time (9:00 a.m. Pacific time)<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Webcast:<\/strong>\n          <\/td>\n<td>\n            <a href=\"https:\/\/us02web.zoom.us\/webinar\/register\/WN_JLeuD8BIRUqWagGnXjhC5A\" rel=\"nofollow\" target=\"_blank\"><br \/>\n              <u>Please click here to register.<\/u><br \/>\n            <\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <br \/>During the webinar, management expects to address the following topics:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">The September 23, 2026 meeting of the FDA\u2019s Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee, at which the panel voted favorably regarding the safety, effectiveness, and overall benefit-risk profile of GRAIL\u2019s Galleri<sup>\u00ae<\/sup> MCED blood test for screening adults aged 50 years and older, and what management believes the panel\u2019s deliberations may indicate about the FDA\u2019s evaluation of MCED tests as a category;<\/li>\n<li style=\"text-align:justify\">What the advisory committee vote may mean for the regulatory and reimbursement strategy 20\/20 BioLabs is pursuing for OneTest\u2122 for Cancer, including the statutory Medicare pathway for FDA-authorized MCED blood tests beginning in 2028 and the Company\u2019s goal of achieving Medicare reimbursement for MCED by the end of 2028;<\/li>\n<li style=\"text-align:justify\">The Company\u2019s newly introduced OneTest\u2122 franchise model, under which independent regional laboratories would offer OneTest\u2122 within defined territories and verticals while 20\/20 BioLabs retains ownership of its machine-learning models, patented methods, and longitudinal biomarker data;<\/li>\n<li style=\"text-align:justify\">Preliminary interest the Company has received from laboratories across the United States and how management believes the franchise model could support broader commercial expansion without the need to build a national sales force; and<\/li>\n<li style=\"text-align:justify\">A live question-and-answer session with management.\n<\/li>\n<\/ul>\n<p align=\"justify\">\u201cThe September 23 advisory committee meeting concerned another company\u2019s test, but we believe many of the questions considered by the panel are relevant to multi-cancer early detection as a broader category,\u201d said Jonathan Cohen, President and Chief Executive Officer of 20\/20 BioLabs. \u201cOn October 7, I look forward to discussing what we believe the meeting may indicate about the regulatory path for MCED tests, where OneTest\u2122 stands today, and how our new franchise model and growing firefighter screening programs could expand access to early cancer detection.\u201d<\/p>\n<p align=\"justify\">The October 7 webinar is part of the Company\u2019s monthly investor webinar series, held on the first Wednesday of each month at 12:00 p.m. Eastern time. Investors and other interested parties are encouraged to submit questions in advance to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JS3AL2t0r3M1kELv8gNvnxkNpUq6rPO8RQyn09RnvsqSWzKwxO6XvFUXIfQEVdZR3vrkNnWtVGUMgTTAOVh9xA==\" rel=\"nofollow\" target=\"_blank\">AIDX@mzgroup.us<\/a>. A replay will be made available through the Company\u2019s investor relations website following the event.<\/p>\n<p align=\"justify\">As part of its commitment to expanding access to early cancer detection, 20\/20 BioLabs will provide webinar attendees with a promotional discount code for OneTest\u2122 at the conclusion of the event. The offer will be available to all attendees, regardless of shareholder status.<\/p>\n<p align=\"justify\">Additional detail on the Company\u2019s business, results of operations, and risk factors is available in its filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The webinar is not expected to include the disclosure of any material non-public information.<\/p>\n<p>\n        <strong>About 20\/20 BioLabs<\/strong>\n      <\/p>\n<p align=\"justify\">20\/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. OneTest\u2122 for Cancer is a multi-cancer early detection blood test and OneTest\u2122 for Longevity measures inflammatory biomarkers and is commercially available. OneTest\u2019s tests are designed to be affordable and accessible and can be conveniently utilized at home using new, upper-arm capillary collection devices as an alternative to traditional venipuncture. Tests are run in the Company\u2019s College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, Maryland.<br \/>For more information visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WrUCfdUwKJSNc-8wwy2fUXb_2sx9UGL56amwyqyFeUMwBpEJXle4Q27KkA6ajTvLI3WUFvx2mL1uWdtAEYgEjxmXbaGRK84Zt4I6Io1Q4XY=\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/2020biolabs.com<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Certain statements in this release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company\u2019s current expectations and projections about future events that it believes may affect its financial condition, results of operations, business strategy, regulatory strategy, reimbursement strategy, growth strategy, acquisition strategy, and financial needs. Forward-looking statements can be identified by words such as \u201cmay,\u201d \u201ccould,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201cintend,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cproject,\u201d \u201ccontinue,\u201d or the negative of these terms or other comparable expressions.<\/p>\n<p align=\"justify\">Forward-looking statements in this release include, but are not limited to, statements regarding the Company\u2019s planned investor webinar and the topics management expects to address. Actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various factors, including the risks described in the Company\u2019s filings with the U.S. Securities and Exchange Commission.<\/p>\n<p align=\"justify\">There can be no assurance that the Company will complete any strategic transaction on any particular timeline, or at all. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events, except as required by applicable law.<\/p>\n<p>\n        <strong>Investor Relations<\/strong><br \/>\n        <br \/>Chris Tyson<br \/>MZ Group<br \/>Direct: 949-491-8235<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JS3AL2t0r3M1kELv8gNvnyJbn2ydY5I59QuYNtAs7Mu-ab_Dbz95tAdCu9TLVbiufsGpj5-9fTol7VrSiRqvGrQSFgTM6AJA6TRLUkiow54=\" rel=\"nofollow\" target=\"_blank\"><u>AIDX@mzgroup.us<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTUxOSM3ODY3OTAyIzIzMDg4ODg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MTAzNjg2MGMtMWNiZS00ZjkzLWE5MmUtY2JiMGE5ZTc1NjRlLTEzMjA0MzgtMjAyNi0wOS0yOS1lbg==\/tiny\/20-20-Biolabs-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>President and CEO Jonathan Cohen to Discuss Implications for Multi-Cancer Early Detection, Preliminary Interest from Laboratories Across the United States, and New State Funding for Firefighter Cancer Screening Webinar to Be Held Wednesday, October 7, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) &#8212; 20\/20 BioLabs, Inc. (Nasdaq: AIDX) (\u201c20\/20 BioLabs\u201d or the \u201cCompany\u201d), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it will host an investor webinar on Wednesday, October 7, 2026, at 12:00 p.m. Eastern time. Jonathan Cohen, President and Chief Executive Officer of 20\/20 BioLabs, will discuss the September 23, 2026 meeting of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;20\/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest\u2122 Franchise Model&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1006631","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>20\/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest\u2122 Franchise Model - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"20\/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest\u2122 Franchise Model - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"President and CEO Jonathan Cohen to Discuss Implications for Multi-Cancer Early Detection, Preliminary Interest from Laboratories Across the United States, and New State Funding for Firefighter Cancer Screening Webinar to Be Held Wednesday, October 7, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) &#8212; 20\/20 BioLabs, Inc. (Nasdaq: AIDX) (\u201c20\/20 BioLabs\u201d or the \u201cCompany\u201d), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it will host an investor webinar on Wednesday, October 7, 2026, at 12:00 p.m. Eastern time. Jonathan Cohen, President and Chief Executive Officer of 20\/20 BioLabs, will discuss the September 23, 2026 meeting of &hellip; Continue reading &quot;20\/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest\u2122 Franchise Model&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-29T14:55:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTUxOSM3ODY3OTAyIzIzMDg4ODg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"20\\\/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest\u2122 Franchise Model\",\"datePublished\":\"2026-09-29T14:55:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\\\/\"},\"wordCount\":1026,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNTUxOSM3ODY3OTAyIzIzMDg4ODg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\\\/\",\"name\":\"20\\\/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest\u2122 Franchise Model - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNTUxOSM3ODY3OTAyIzIzMDg4ODg=\",\"datePublished\":\"2026-09-29T14:55:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNTUxOSM3ODY3OTAyIzIzMDg4ODg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNTUxOSM3ODY3OTAyIzIzMDg4ODg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"20\\\/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest\u2122 Franchise Model\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"20\/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest\u2122 Franchise Model - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\/","og_locale":"en_US","og_type":"article","og_title":"20\/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest\u2122 Franchise Model - Market Newsdesk","og_description":"President and CEO Jonathan Cohen to Discuss Implications for Multi-Cancer Early Detection, Preliminary Interest from Laboratories Across the United States, and New State Funding for Firefighter Cancer Screening Webinar to Be Held Wednesday, October 7, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) &#8212; 20\/20 BioLabs, Inc. (Nasdaq: AIDX) (\u201c20\/20 BioLabs\u201d or the \u201cCompany\u201d), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it will host an investor webinar on Wednesday, October 7, 2026, at 12:00 p.m. Eastern time. Jonathan Cohen, President and Chief Executive Officer of 20\/20 BioLabs, will discuss the September 23, 2026 meeting of &hellip; Continue reading \"20\/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest\u2122 Franchise Model\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-29T14:55:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTUxOSM3ODY3OTAyIzIzMDg4ODg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"20\/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest\u2122 Franchise Model","datePublished":"2026-09-29T14:55:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\/"},"wordCount":1026,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTUxOSM3ODY3OTAyIzIzMDg4ODg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\/","name":"20\/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest\u2122 Franchise Model - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTUxOSM3ODY3OTAyIzIzMDg4ODg=","datePublished":"2026-09-29T14:55:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTUxOSM3ODY3OTAyIzIzMDg4ODg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTUxOSM3ODY3OTAyIzIzMDg4ODg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-october-7-2026-to-discuss-fda-advisory-committee-vote-and-new-onetest-franchise-model\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"20\/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest\u2122 Franchise Model"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1006631"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006631\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1006631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1006631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1006631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}